Cargando…

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function

Many antibiotics require dose adjustments in patients with renal impairment and/or in those undergoing hemodialysis. Omadacycline, the first aminomethylcycline antibiotic in late-stage clinical development, displays activity against a broad spectrum of bacterial pathogens, including drug-resistant s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, Jolene K., Tzanis, Evan, Garrity-Ryan, Lynne, Bai, Stephen, Chitra, Surya, Manley, Amy, Villano, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786750/ https://www.ncbi.nlm.nih.gov/pubmed/29158281 http://dx.doi.org/10.1128/AAC.02057-17

Ejemplares similares

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants
por: Tzanis, Evan, et al.
Publicado: (2016)

The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
por: Hunt, Thomas L., et al.
Publicado: (2020)

Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of (14)C-Omadacycline in Rats
por: Lin, Wen, et al.
Publicado: (2016)

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
por: Sun, Haiying, et al.
Publicado: (2016)

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
por: Kovacs, Steven J., et al.
Publicado: (2020)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2019)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline
por: Tanaka, S. Ken, et al.
Publicado: (2016)

1356. Improvement in Quality of Life for Adults With Acute Bacterial Skin and Skin Structure Infections Following Treatment With Omadacycline or Linezolid
por: Tzanis, Evan, et al.
Publicado: (2018)

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
por: Bruss, Jon B., et al.
Publicado: (2023)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro
por: Serio, Alisa W, et al.
Publicado: (2021)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
por: Bich Hanh, Bui Thi, et al.
Publicado: (2021)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
por: Trang, M., et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2021)

In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis
por: Steenbergen, Judith, et al.
Publicado: (2017)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iit07khu4ok3tjskrg8f86ko72